Supporting Access & Commercialisation in Rare Diseases
ENTRI Access2Rare empowers rare disease biotech and pharmaceutical companies to successfully navigate market access and launch therapies across Europe. With deep expertise in regulatory strategy, payer engagement, HTA navigation, launch readiness, commercialisation and digital engagement, we help ensure your orphan drug reaches the patients who need it - efficiently and compliantly. Based in Europe, we support clients across the EU with tailored solutions spanning early access, reimbursement, launch and market implementation.
From Rare Disease Therapy to Patient Access
ENTRI is driven by a singular purpose: to assist companies in achieving successful reimbursement and seamless product launches in select countries across Europe. With our in-depth knowledge of the healthcare landscape in the region, we specialize in navigating complex reimbursement systems and overcoming market access barriers.
What sets us apart is our unrivaled expertise in negotiating access for rare therapies. Our team of seasoned commercialization experts possesses a deep understanding of the unique challenges faced by companies in this space. We leverage this knowledge to craft tailored strategies and provide invaluable support throughout the entire product lifecycle.
Partnering with ENTRI means working with a team dedicated to your success. We are committed to delivering exceptional results, helping you overcome hurdles, and ensuring your breakthrough therapies reach the patients who need them most. With our comprehensive approach and unwavering focus on excellence, we are your trusted ally in the journey towards improved patient outcomes.
Together, let's redefine the landscape of healthcare access, create meaningful change, and make a lasting impact in the lives of patients across Europe!
Flexible Resourcing for Lean Teams
Bridge internal resource and expertise gaps with senior external support.
Commercializing a product in Europe requires resources many biotech teams don’t have in-house. ENTRI provides flexible, senior-level support for market access, pricing, and launch execution - when internal capacity is limited or stretched.
Local Market Access Expertise Across Europe
Navigate country-specific reimbursement with confidence.
Each EU country has its own HTA system, pricing pathway and stakeholder expectations. ENTRI brings deep local insight, native-language skills and experience engaging with key experts and patient advocacy groups (PAGs) to help you shape and execute successful access strategies tailored to each market.
End-to-End Rare Disease Launch Experience
ENTRI combines strategic insight with practical experience across European rare disease launches. From early planning and payer negotiations to commercialisation and digital engagement, we support your team with proven methods, tailored digital solutions and actionable plans that turn strategy into effective market execution.
Scalable Support for Shifting Priorities
Stay agile as timelines, pipelines and business needs change.
Biotech companies face constant change - shifting timelines, evolving pipelines, and unexpected challenges. ENTRI helps you stay on track by taking ownership of specific market access or launch activities, so you can focus on what’s next.
Our services are designed to help you successfully launch in Europe
ENTRI has extensive experience in commercializing orphan drugs across (Northern) Europe. We build the optimal launch strategy across the region, by country and successfully manage the execution. We custom build our team based on your unique needs; ensuring a targeted and cost-efficient approach.
Unlock Rare Disease Solutions
Partner with ENTRI Access2Rare for expert consultancy that simplifies market entry and accelerates patient access to rare disease treatments in Europe.